RT @brummendorf@twitter.com

Great #ASH2022 presentation of the interim analysis of the first 95 ET patients treated within the #RuxoBEAT trial showing superiority in symptom score improvement in the #ruxolitinib arm by ⁦@KoschmiederS@twitter.com⁩ from ⁦@UniklinikAachen@twitter.com⁩ ⁦@RWTH@twitter.com⁩ ⁦@GsgMpn@twitter.com⁩ #CRU344

🐦🔗: https://twitter.com/brummendorf/status/1602357032857862144